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Available online 1 February 2019Background: Histone deacetylase 4 (HDAC4) has been proposed as a target for Amyotrophic Lateral Sclerosis
(ALS) because itmediates nerve-skeletal muscle interaction and since its expression in skeletalmuscle correlates
with the severity of the disease. However, our recent studies on the skeletal muscle response upon long-term
denervation highlighted the importance of HDAC4 in maintaining muscle integrity.
Methods: To fully identify the yet uncharacterizedHDAC4 functions in ALS, we genetically deletedHDAC4 in skel-
etal muscles of a mouse model of ALS. Body weight, skeletal muscle, innervation and spinal cord were analyzed
over time bymorphological andmolecular analyses. Transcriptome analysis was also performed to delineate the
signaling modulated by HDAC4 in skeletal muscle of a mouse model of ALS.
Findings: HDAC4 deletion in skeletal muscle caused earlier ALS onset, characterized by body weight loss, muscle
denervation and atrophy, and compromised muscle performance, although the main catabolic pathways were
not activated. Transcriptome analysis identified the gene networks modulated by HDAC4 in ALS, revealing
UCP1 as a top regulator that may be implicated in worsening ALS features.
Interpretation: HDAC4 plays an important role in preserving innervations and skeletal muscle in ALS, likely by
modulating the UCP1 gene network. Our study highlights a possible risk in considering HDAC inhibitors for the
treatment of ALS.
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ALS1. Introduction
Amyotrophic Lateral Sclerosis is a neurodegenerative disorder char-
acterized bymotor neuron degeneration, skeletal muscle weakness and
atrophy, fasciculation, speech and swallowing disabilities, progressive
paralysis and, eventually, death by respiratory failure. Prognosis varies
from few months to few years, although the majority of patients do
not exceed 19 months since diagnosis and 30 months after the onset
of the symptoms. About 20% of the familial cases of ALS are caused by
one among over 150 mutations in the Cu/Zn superoxide dismutase 1
(SOD1) gene, mostly autosomal dominant [1]. In physiological condi-
tions, SOD1 protects the cell from the accumulation of free radicals byi).
. This is an open access article underconverting the superoxide anion, derived frommitochondrial oxidative
phosphorylation, to water or hydrogen peroxide [1]. For years ALS has
been considered a pure motor neuron disease exclusively. Coherently
with this theory, viral delivery of siRNA for themutant SOD1 accumula-
tion in skeletal muscle was not able to counteract ALS disease in mice,
demonstrating that skeletal muscle is not a significant contributor to
ALS [2]. However, more recently, it is emerging that motor neuron de-
generation is a non-cell-autonomous phenomenon, involving numer-
ous cell types. For instance, microglial cells actively participate in
neuroinflammation by secreting pro-inflammatory cytokines [3], and
skeletalmuscle activates retrograde signals that influencemotor neuron
survival and ALS progression [4]. By generating transgenic mice, two in-
dependent studies demonstrated that themuscle-specific expression of
themutated SOD1 gene recapitulates some pathological features of ALS,
including severe myopathy, neuromuscular junction (NMJ) abnormali-
ties and motor neuron degeneration [5,6]. One of the retrograde signalsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
HDAC4 is a stress-responsive epigenetic factor whose expression
is strongly up-regulated in skeletal muscle of Amyotrophic Lateral
Sclerosis (ALS) patients and ofmice following denervation, where
it mediates skeletal muscle response to denervation. Therefore,
HDAC4 has been proposed as a therapeutic target for muscular
pathologies characterized by neurogenic muscle atrophy. How-
ever, pan-HDAC inhibitors failed in a phase-II clinical trial. More-
over, specific inhibition of class II HDACs had no effects on body
weight loss and survival in ALS mice. Understanding the molecu-
lar mechanism underlying ALS progression and modulated by
each HDAC is a prerequisite to ameliorate the therapy presently
in use.
Added value of this study
In this study, we dissected the role of HDAC4 in ALS pathogene-
siswith a genetic approach. Deletion of HDAC4 in skeletal muscle
accelerated the pathological features of ALS, preceding and exac-
erbating skeletal muscle loss and denervation, by modulating sev-
eral biological processes and an interesting gene network in ALS
skeletal muscle.
Implications of all the available evidence
We elucidated a pivotal role of HDAC4 in mediating skeletal mus-
cle homeostasis in ALS. Our study provides new experimental
bases for reconsidering the use of pan-HDAC inhibitors as a phar-
macological treatment for ALS.
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sion is mediated by the microRNAs miR-206 and its downstream target
histone deacetylase 4 (HDAC4) [7].
HDAC4 is a class IIa HDAC stress-responsive epigenetic factor that
mediates skeletal muscle response to denervation through transcrip-
tional and cytoplasmic actions. Upon denervation, HDAC4 transcription
is significantly induced in the skeletal muscle, where it represses the
transcription of the Dach2 gene and activates the MAPK-AP1 signaling
cascade in the cytoplasm, thereby promoting neurogenic muscle atro-
phy by two independent pathways converging on the E3 ubiquitin-
ligases MuRF1 and atrogin-1 transcription [8–10]. Moreover, by indi-
rectly regulating myogenin expression, HDAC4 is responsible for the
transcriptional activation of synaptic acetylcholine receptors, MuSK,
andmiR-206, thus promotingmuscle reinnervation [7,10]. Consistently,
mice with a muscle-specific deletion of HDAC4 are resistant to neuro-
genic atrophy and reinnervate faster than controls mice [7,9].
HDAC4 has been proposed as a therapeutic target for muscular pa-
thologies characterized by neurogenic muscle atrophy [11], because of
its crucial role in mediating skeletal muscle response to innervation
and since its expression in skeletal muscle correlates with the severity
of the ALS progression [12,13]. Accordingly, pan-HDAC inhibitors
(HDACi), which unspecifically block the activities of class I and II
HDACs, restored muscle mass and function and prolonged the survival
of a murine model of ALS [14–16]. However, these compounds failed
in a phase-II clinical trial [17,18]. Importantly, no changes in the expres-
sion of the different members of the HDAC superfamily were registered
in the spinal cords of ALS mice, while a significant increase in the ex-
pression of the members of class II HDACs was detected in the skeletal
muscle with the progression of the disease [19]. Specific inhibition ofclass II HDACs in ALS mice induced motor improvement and increased
skeletalmuscle electrical potentials, although no effects on bodyweight
loss or survivalwere registered [19]. Low inhibitory efficiency and a lack
of selectivity are two of the possible reasons for the low efficacy of the
treatment. The inhibition of all the members of class II HDACs, more-
over, does not clarify the mechanisms underlying ALS progression.
Understanding the molecular mechanism modulated by each HDAC,
with a genetic approach, is a prerequisite to ameliorate the therapy
presently in use.
In this study,we dissected the role of HDAC4 in ALS pathogenesis, by
generating SOD1G93A (SOD) mice with a skeletal muscle-specific dele-
tion of HDAC4 (SOD HDAC4mKO mice). Deletion of HDAC4 in skeletal
muscle worsened the pathological features of ALS, preceding and exac-
erbating skeletal muscle loss and denervation. Moreover, HDAC4 mod-
ulated several biological processes and an interesting gene network in
ALS skeletal muscle. Considering the pivotal role of HDAC4 inmediating
skeletal muscle response to ALS, our study provides new experimental
bases for the development of new pharmacological treatments for ALS.
2. Materials and methods
2.1. Mice
HDAC4 conditional mutant mice were generously provided by Prof.
Eric N Olson and Rhonda Bassel-Duby. The reduction of HDAC4 expres-
sion in skeletal muscle was confirmed by real-time PCR and western
blot analyses in HDAC4mKOmice, compared to controls (CTR) (Supple-
mentary Fig. S1a–c). To study the role of HDAC4 in ALS, Hdac4fl/fl
myogenin;Cre mice were crossed with the SOD1G93A transgenic mice
(Charles River Laboratories). After several breedings, SOD1G93A Hdac4-
fl/fl myogenin;Cre mice (mice with ALS disease and HDAC4 deletion in
skeletal muscle, called SOD HDAC4mKO mice) and SOD1G93A Hdac4fl/fl
mice (mice with ALS disease and homozygous for a floxed Hdac4 allele,
referred to as SODmice) were obtained (Fig. 1). In all the experiments,
male SOD HDAC4mKO and SOD mice from the same litter were com-
pared, in order to define HDAC4 function in skeletal muscle in ALS, de-
spite the different genetic backgrounds. In addition, Hdac4fl/fl healthy
control (CTR) mice of the same sex and age were used (whenever pos-
sible from the same litter, always from the same colony).
2.2. Ethics statement
Mice were treated in strict accordance with the guidelines of the In-
stitutional Animal Care and Use Committee, as well as national and
European legislation, throughout the experiments. Animal protocols
were approved by the Italian Ministry of Health (authorizations #
244/2013 and # 853/2016-PR).
2.3. Replicates
The differences between SOD and SOD HDAC4mKO mice were con-
firmed in independent experiments, i.e., independent litters, by consid-
ering as “n” an independent biological sample, not a technical replicate.
2.4. Functional analyses
Muscle strength analyses were performed by grip test. The grip-
strength meter (Ugo Basile) consists of a T-shaped bar connected to a
force transducer, in turn connected to the peak amplifier 47,105–001.
Mice were held by the tail and allowed to grab the bar. Mice were
then pulled backward, exerting a constant force until they lost the
grip. The force applied to the bar is recorded as the peak tension. To ob-
tain reproducible data, each animal was subjected to 10 consecutive
measurements, and the mean value was used as a single measurement.
Fig. 1.Breeding strategy.Hdac4fl/flmyogenin;Cremalemicewere crossedwithHdac4wt/wt SOD1G93A femalemice (F0: Founders). In theF1breeding,Hdac4fl/flmyogenin;Cremalemicewere
crossed with Hdac4fl/wt SOD1G93A female mice, to obtain Hdac4fl/fl SOD1G93A mice. Hdac4fl/flmyogenin;Cre males were then crossed with Hdac4fl/fl SOD1G93A females in F2 and, from the
litters, only SOD1G93Amale mice were used in the experiments: either Hdac4fl/fl (SODmice) or Hdac4fl/flmyogenin;Cre (SOD HDAC4mKOmice); Hdac4fl/fl as healthy controls (CTRmice).
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For innervations and spinal cord histological analyses, mice were
perfused by using “In Vivo Perfusion System 140 ml” (2Biological In-
struments). A heparinized (10 units/ml) (Sigma-Aldrich, Saint Louis,
Missouri, #84020), in 0.9% NaCl (Sigma-Aldrich, Saint Louis, Missouri,
#31434) in water and a 4% paraformaldehyde fixative (Sigma-Aldrich,
Saint Louis, Missouri, #1.00496), in PBS: 37 mM NaCl (Sigma-Aldrich,
Saint Louis, Missouri, #31434-M); 2.7 mM KCl (Sigma-Aldrich, Saint
Louis, Missouri, #P3911); 4.3 mM Na2 HPO4 (Sigma-Aldrich, Saint
Louis, Missouri, #S0876); 147 mM KH2PO4 pH 7.4 (Sigma-Aldrich,
Saint Louis, Missouri, #P0662) solutions were used. The animals were
anesthetized with intraperitoneal (i.p.) injections of 50 mg/Kg Zoletil
(Bioz, Los Altos, California) and 10 mg/Kg Xylazine (Sigma-Aldrich,Saint Louis, Missouri, #X1126). To guarantee access to the heart, a tho-
racotomy was performed, by cutting the ribs and preventing heart and
lung damage. The perfusion needle was inserted into the left ventricle,
while the right atriumwas cut to create away out for the blood and per-
fusion fluids, avoiding pressure overloads. The animals were then firstly
perfusedwith the heparinized solution to remove blood from the circu-
lation, and then with the fixative solution. The tail stiffness was used as
an index of efficient perfusion.
2.6. Histological analyses
To reduce the numbers of mice in our experiments, considering that
a similar phenotype was observed in the Tibialis Anterior (TA) and Gas-
trocnemius (GA) muscles, TA muscles were consistently used for
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embedded in tissue freezing medium (Leica, Wetzlar, Germany) and
frozen in liquid nitrogen pre-cooled isopentane (Sigma-Aldrich, Saint
Louis, Missouri, # PHR1661). Cryosections (8 μm or 20 μm) were ob-
tained by using a Leica cryostat.
Ventral spinal cords were isolated fromperfusedmice, embedded in
tissue freezing medium (Leica, Wetzlar, Germany) and frozen in liquid
nitrogen pre-cooled isopentane (Sigma-Aldrich, Saint Louis, Missouri,
# PHR1661). Cryosections (16 μm) were obtained by using a Leica
cryostat.
Hematoxylin and eosin (H&E) (Sigma-Aldrich, Saint Louis, Missouri,
# H3136 and # 861006) staining was performed according to the
Sigma-Aldrich manufacturer's instructions. Cryosections of spinal
cords (16 μm) were also stained with NISSL staining (Sigma-Aldrich,
Saint Louis, Missouri, #C5042), performed according to the Sigma-
Aldrich manufacturer's instructions.
2.7. Immunofluorescences
Cryosections were fixed in 4% formaldehyde (Sigma-Aldrich, Saint
Louis, Missouri, #F8775) for 10 min at room temperature, then washed
and blocked with 1% BSA (Sigma-Aldrich, Saint Louis, Missouri,
#A9647) and 0.2% Triton (Sigma-Aldrich, Saint Louis, Missouri, #
X100) for 1 h. Samples were then incubated with a 1:100 dilution in
1% BSA of rabbit polyclonal anti-Neurofilament antibody (Genetex,
Hsinchu City, Taiwan, # GTX110065) or 1:200 anti-p62/SQSTM1 (C ter-
minus) (Progen, #GP62-C) overnight at 4 °C, followed by incubation
with a 1:500 dilution in 1% BSA of Alexa Fluor 568 anti-rabbit
(ThermoFisher, Waltham, Massachusetts, #A11011) and α-
bungarotoxin Alexa fluor-488 conjugate (ThermoFisher, Waltham,
Massachusetts, # B13422), or Alexa Fluor 488 anti-guinea pig IgG
(ThermoFisher, Waltham, Massachusetts, #A11073) for one hour at
room temperature. Nuclei were stained with TO-PRO-3 iodide
(ThermoFisher, Waltham, Massachusetts, #T3605).
2.8. Morphometric analyses
Myofiber cross-sectional area and p62 fluorescence were quantified
on H&E or immunostained sections, respectively, by using Image J soft-
ware. The entire muscle section was quantified for each sample.
NMJ images were collected using Leica software (Leica
Microsystems) and analyzed using ImageJ software. Endplate and
AChR areas were analyzed using “NMJ-morph” ImageJ plugin [20]. Per-
foration area was calculated by subtraction of AChR area from endplate
area.
Innervation was quantified using images acquired with on confocal
microscope LEICA-DM-IRE2 (LCSSP2) equipped with LEICA TSCSP2
laser and DC500 camera. About 20 NMJswere quantified per mouse. In-
nervation was evaluated based on the overlap between neurofilament
and postsynaptic (α-488 bungarotoxin) components. About 23 NMJs
were quantified per mouse.
2.9. RNA extraction and real-time PCR
To reduce the numbers of mice in our experiments, considering that
a similar phenotype was observed in the TA and GA muscles, GA mus-
cles were consistently used for gene expression analyses. Total RNA
was isolated and purified from 30 to 50 mg of GA muscles by using
Trizol (Invitrogen, Carlsbad, California, #15596018), following theman-
ufacturer's protocol. One microgram of total RNA was converted to
cDNA by using the PrimeScript™ RT reagent Kit (Takara, Kyoto, Japan,
#RR047A). Real-time PCR was performed with the SDS-ABI Prism
7500 (Applied Biosystem) by using the Sybr Green reaction mix (Ap-
plied Biosystem, Foster City, California, #4368577). Gapdh was used as
loading control. For micro-RNAs, RT-PCR was performed by using the
TaqMan MicroRNA Reverse Transcriptase kit (Applied Biosystems)and the specific primers formiR-206 and U6, as loading control, accord-
ing to the manufacturer's recommendations. miR-206 expression was
analyzed by quantitative real-time PCR, using TaqMan™ MicroRNA
Assay (Applied Biosystems).
The primer sequences used are reported below:
Hdac4 for: GTCTTGGGAATGTACGACGC.
Hdac4 rev: GTTGCCAGAGCTGCTATTTG.
Atrogin1 for: GCAAACACTGCCACATTCTCTC.
Atrogin1 rev: CTTGAGGGGAAAGTGAGACG.
MuRF1 for: ACCTGCTGGTGGAAAACATC.
MuRF1 rev: CTTCGTGTTCCTTGCACATC.
LC3b for: CACTGCTCTGTCTTGTGTAGGTG.
LC3b rev: TCGTTGTGCCTTTATTATTAGTGCATC.
p62 for: CCCAGTGTCTTGGCATTCTT.
p62 rev: AGGGAAAGCAGAGGAAGCTC.
Myogenin for: GCACTGGAGTTCGGTCCCAA;
Myogenin rev: TATCCTCCACCGTGATGCTG.
Chrna1 for: CTCTCGACTGTTCTCCTGCTG;
Chrna1 rev: GTAGACCCACGGTGACTTGTA.
Chrng for: GGAGAAGCTAGAGAATGGTCC;
Chrng rev: CCCACTGACAAAGTGACTCTGC.
Dach2 for: ACT GAA AGT GGC TTT GGA TAA.
Dach2 rev: TTC AGA CGC TTT TGC ATT GTA.
UCP1 for: CGACTCAGTCCAAGAGTACTTCTCTTC.
UCP1 rev: GCCGGCTGAGATCTTGTTTC.
SOD1 for: CAC TTC GAG CAG AAG GCA AG.
SOD1 rev: CCC CAT ACT GAT GGA CGT GG.
Gapdh for: ACCCAGAAGACTGTGGATGG.
Gapdh rev: CACATTGGGGGTAGGAACA.2.10. Protein extraction and western blot analyses
GA muscles or ventral roots of spinal cords were dissected, minced,
and homogenized in lysis buffer (50 mM Tris HCl pH 7.4) (Sigma-Al-
drich, Saint Louis, Missouri, #RES 3098 T-B7); 1 mM EDTA (VWR, Rad-
nor, Pennsylvania, #A10713.36); 150 Mm NaCl (Sigma-Aldrich, Saint
Louis, Missouri #31434-M), 1% Triton (Sigma-Aldrich, Saint Louis, Mis-
souri, #X100) supplemented with protease (Sigma-Aldrich, Saint Louis,
Missouri, #P8340) and phosphatase inhibitors (Sigma-Aldrich, Saint
Louis, Missouri, #P2850). Proteins (30–50micrograms) were separated
by SDS-PAGE and transferred to nitrocellulose membrane (GE
Healthcare Life science Amersham, #10600002) for one hour. For
poly-ubiquitinated proteins, proteins were transferred overnight, and
membranes were boiled for five minutes. Unspecific binding was
blocked with 5% not fat dry milk (Santa Cruz, California, #sc-221188)
in TBST buffer: 20 mM Tris HCl ph 7.6 (Sigma-Aldrich, Saint Louis, Mis-
souri, #RES 3098 T-B7); 137 mMNaCl (Sigma-Aldrich, Saint Louis, Mis-
souri, #31434-M); 0.5% Tween 20 (Santa Cruz, California, #SC-29113),
and themembraneswere incubated overnight, at 4 °C, with primary an-
tibody diluted in 5%BSA (Sigma-Aldrich) in TBST. Afterwashing in TBST,
membranes were incubated with secondary antibodies HRP-conjugate
(BIO-RAD, Hercules, California, #170–6515 or 170–6516) and signals
were detected by using ECL chemistry (Advansta, Menlo Park, Califor-
nia, #K-12045-D20). Images were acquired using films or ChemiDoc
MP imaging system (BIO-RAD). Anti-alpha tubulin was used as loading
control because its expression resulted unaffected by experimental
models. Densitometric analyses were performed bymeasuring band in-
tensity for each sample using Image J software. For the anti-ubiquitin
western blots, the intensity of all the bands in themembranewas quan-
tified. The following primary antibodieswere used: HDAC4 (Santa Cruz,
California, #sc-11418), Gapdh (Santa Cruz, California, #sc-32233),
Alpha-tubulin (Sigma-Aldrich, # T5168), Ubiquitin (Stressgen, San
Diego, California, #SPA-203), LC3b (Cell Signaling, Danvers, Massachu-
setts, #2775), p62 (Sigma-Aldrich, Saint Louis, Missouri, #P0067),
Chat (Millipore, Burlington, Massachusetts, #AB144P).
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Proteasome activity was assessed as previously described in [21].
Briefly, GAmuscleswere isolated,minced, and homogenized inwestern
blot lysis buffer. Ten micrograms of proteins were used for measuring
proteasome activity, by using the CHEMICON Proteasome Activity
Assay Kit (Millipore, Burlington, Massachusetts, #APT280) following
manufacturer's instructions.
2.12. Next generation sequence analysis
Total RNA was harvested from five SOD and six SOD HDAC4mKO
mice. Samples were pooled together and sequenced as duplicates. Anal-
yses were performed at the IGA Technology Services Srl, Udine, Italy. Li-
brarieswere generated from total RNA fromGAmuscles of 14-week-old
mice, using the Stranded mRNA Sample Prep kit” (Illumina, San Diego,
CA) and sequenced using HiSeq2500 (Illumina, San Diego, CA). Data
were deposited in GEO (reference Series number: GSE121789).
2.13. Bioinformatic analyses
On average 56.4million readswere produced per sample. Read qual-
itywas asserted through FastQC, and quality/adapter trimmingwas car-
ried out using Cutadapt. Subsequently, reads were pseudoaligned to
transcriptome GRCm38 (mm10) using Kallisto version 0.43.1. Subse-
quently, count tables were generated in R using tximport together
with DESeq2 [22]. Differential expression of genes was conducted
using DESeq2 with default options. Genes were considered differen-
tially expressed if the p-value wasb0.05. Gene ontology analyses and
gene networks were obtained by David software (https://david.ncifcrf.
gov) or by Ingenuity pathway analysis (QIAGEN Redwood City, www.
qiagen.com/ingenuity). Over-representation analysis was carried out
using the R packages DOSE and ReactomePA [23,24]. The significance
of enrichment is determined through application of the hypergeometric
test.
2.14. Statistics and program
Statistical significancewas determined byusing two-tailed Student's
t-test when two conditions were compared, or with one-way or two-
way analysis of variance (ANOVA), followed by Tukey's HSD test as a
post-hoc test, when more than two conditions needed to be compared.
All valueswere expressed asmean± standard error of themean (SEM).
VassarStats, a statistical computation website available at http://
vassarstats.net/, was used for the statistical analyses. The Kaplan–
Meier analysis with Log-rank (Mantel-Cox) test was used for ALS
onset, progression and mouse survival. All the artwork was created by
using Sigma Plot program.
3. Results
3.1. HDAC4 expression is modulated in a murine model of ALS
Increased HDAC4 expression in skeletalmuscle has been reported to
occur in SODmice or ALS patients [10,12,19]. To evaluate the expression
levels of HDAC4 in ALS over time, we analyzed HDAC4 mRNA and pro-
tein expression levels in the GA muscles of SOD mice, at a preonset
(12 weeks) and at a symptomatic (15 weeks) stage, compared to
healthy control (CTR) muscles. HDAC4 mRNA and protein levels were
significantly upregulated in skeletal muscle at a preonset stage and de-
creased at 15 weeks of age (Fig. 2a–c).
To delineate HDAC4 functions in skeletal muscle in ALS, mice with a
muscle-specific deletion of HDAC4 [25] (referred to as HDAC4mKO
mice), in which the reduction of HDAC4 expression in skeletal muscle
was confirmed by real-time PCR and western blot analyses (Supple-
mentary Fig. S1a-c), were crossed with SOD mice, generating SODHDAC4mKOmice (Fig. 1). Real-time PCR andwestern blot analyses con-
firmed a significant reduction of HDAC4 expression in SOD HDAC4mKO
muscles, compared to SOD littermates, at 12weeks of age (Fig. 2d–f). In-
stead, no significant changes in HDAC4 expression were registered in
spinal cords among healthy CTR, SOD, and SOD HDAC4mKO mice
(Fig. 2g–i).
3.2. Deletion of HDAC4 exacerbates ALS phenotype
Body weight is a widely used parameter to assess the onset of ALS
and to stage it. Therefore, to define the role of HDAC4 in ALS, we moni-
tored the ALS onset and progression in male SOD HDAC4mKO and SOD
littermates, by measuring mouse weight over time, compared to male
healthy male control (CTR) mice. While CTR mice continued to gain
weight over time, SOD mice reached the maximum body weight at
14weeks of age anddeletion ofHDAC4 in skeletalmuscle induced a pre-
cocious and exacerbated body weight loss in SOD HDAC4mKO mice
(Fig. 3a). HDAC4 deletion in SOD mice significantly shortens ALS onset
(Fig. 3b, c), defined as the time when the body mass starts to decline.
Conversely, ALS progression, defined as the time from the onset of the
disease to the death of the animal, did not significantly change between
SOD HDAC4mKO and SOD mice (Fig. 3d, e). To assess if HDAC4 also af-
fects muscle strength, a grip-test at the preonset stage (i.e., 12 weeks,
when HDAC4 expression resulted significantly induced in SOD skeletal
muscle) was performed. Importantly, while no significant differences
were registered between healthy and SOD mice, SOD HDAC4mKO
mice showed a significant reduction in muscle force as soon as
12 weeks of age, compared to SOD littermates and healthy CTR mice
(Fig. 3f). Moreover, HDAC4 deletion exacerbated the disease features
of SODmice, including bodyweight loss, tremor, and kyphosis, although
mouse lifespan was not significantly affected (Fig. 3g, h). Of note,
HDAC4mKO mice at baseline did not show significant differences in
body weight or muscle strength (Supplementary Fig. S1d, e) as previ-
ously reported [9,25].
3.3. Muscle atrophy correlates with body weight loss in SOD HDAC4mKO
mice
To verify if the bodyweight loss correlatedwithmusclemass loss, TA
muscles were weighted, and histological analyses were performed at
different ages. At 12 weeks (preonset stage), no significant differences
in muscle mass or histology were observed between SOD and SOD
HDAC4mKO littermates (Fig. 4a, d), despite a significant decrease in
muscle mass was registered versus CTR mice. Morphometric analyses
of myofiber cross-sectional area (CSA) distribution confirmed these ob-
servations, highlighting a significant difference between CTR and either
SOD or SOD HDAC4mKO TA myofibers in the 2001–2500 and N 3501
square micron classes (Fig. 4e). At 15 weeks (symptomatic stage), the
differences between CTR and SOD or SOD HDAC4mKO mice persisted
(Fig. 4b, f, g). Moreover, a significant reduction in muscle mass was ap-
parent in SOD HDAC4mKOmice, compared to SOD littermates (Fig. 4b).
Histological and morphometric analyses highlighted a significant in-
crease in the number of small myofibers (501–1500 square micron)
and a significant concomitant decrease in the number of big myofibers
(2501–3500 square micron) in SOD HDAC4mKO TAmuscles compared
to SOD littermates, indicative of muscle atrophy (Fig. 4g). At 18 weeks
(late stage), the reduction in SOD and SOD HDAC4mKO TA weight
persisted, compared to CTRmice (Fig. 4c). Moreover, the differences be-
tween SOD and SOD HDAC4mKO TA weight remained (Fig. 4c). Histo-
logical and morphometric analyses highlighted that, while SOD mice
were characterized by myofibers with heterogeneous size, SOD
HDAC4mKOmice showedmore pronouncedmuscle atrophy, character-
ized by a significantly higher number of smaller myofibers (1001–1500
square micron) and a lower number of bigger myofibers (3001–3500
square micron) (Fig. 4h, i). A similar phenotype was observed in the
GA muscles (Supplementary Fig. S2), allowing us to consistently use
Fig. 2.HDAC4 expression ismodulated in the skeletalmuscle of SOD andSODHDAC4mKO. (a) Hdac4 expression inGAmuscles of SODmice, at 12 and 15weeks of age, overhealthy control
(CTR) muscles, by real-time PCR. Data are expressed as mean +/− SEM. n= 4 mice for each condition. (One-way ANOVA reveals a significant effect: F = 14.34; df 2; p= 0.003; and
interaction: *p b 0.05 and **p b 0.01 by Tukey's HSD test). (b) Western blot analyses and (c) densitometry for HDAC4 in GA muscles of CTR and SOD mice, at 12 and 15 weeks of age.
Alpha-tubulin was used as a loading control. Data are expressed as mean +/− SEM. n= 3 mice for each condition. (One-way ANOVA reveals a significant effect: F = 57.25; df 2; p b
0.0001; and interaction: **p b 0.01 by Tukey's HSD test). (d) Hdac4 expression in GA muscles of SOD and SOD HDAC4mKO mice, by real-time PCR, at 12 weeks of age. Data are
expressed as mean +/− SEM. n = 4 SOD; n = 5 SOD HDAC4mKO. (**p b 0.01 by Student's t-test.) (e) Western blot analyses and (f) densitometry for HDAC4 in GA muscles of SOD
and SODHDAC4mKOmice, at 12 weeks of age. Alpha-tubulinwas used as a loading control. Data are expressed asmean+/− SEM. n= 3mice for each genotype. (**p b 0.01 by Student's
t-test). (g) Hdac4 expression in SOD and SOD HDAC4mKO spinal cords, by real-time PCR, at 12 weeks of age. Data are expressed asmean +/− SEM. n = 4 SOD; n= 5 SOD HDAC4mKO.
(h)Western blot analyses and (i) densitometry for HDAC4 in SOD and SODHDAC4mKO spinal cords, at 12 weeks of age. Gapdhwas used as a loading control. Data are expressed asmean
+/− SEM. n = 3 mice for each condition.
722 E. Pigna et al. / EBioMedicine 40 (2019) 717–732TA muscles for histological evaluations and GA muscles for molecular
biology analyses, to reduce the mouse number in our experiments. Im-
portantly, no significant changes in TA weight, histology or fiber CSA
distribution were registered in HDAC4mKO mice at baseline (Supple-
mentary Fig. S1f–h), as previously reported [9,25].
3.4. HDAC4 affects NMJs and innervation in ALS
NMJ degeneration and muscle denervation are the two main fea-
tures of ALS that precede and contribute to neurogenic muscle atrophy.
To evaluate if the HDAC4 deletion affected NMJ shape, acetylcholinereceptors (AChRs) were labeled using fluorescently conjugated
Bungarotoxin (BTX) in healthy CTR, SOD and SOD HDAC4mKO TAmus-
cles, and the synaptic areas were analyzed at different ages. At a
preonset stage, no apparent differences in NMJ morphology were
observed among the experimental groups (data not shown). At
15 weeks, however, SOD HDAC4mKO mice had reduced NMJ surface
area as compared to SOD littermates or healthy CTR mice, while no
major differences were observed between CTR and SOD mice (Fig. 5a,
b). This reduction was associated with a decrease of the area occupied
by AChRs, as well as of the area of perforations between AChR-rich re-
gions [26] (Fig. 5c, d). To evaluate if HDAC4 deletion affects NMJ
Fig. 3. Genetic deletion of HDAC4 in skeletal muscle exacerbates the pathological features of ALS in male mice. (a) Body weight of healthy control (CTR), SOD and SOD HDAC4mKOmice,
normalized to the bodyweight at 9weeks. Data are expressed asmean+/− SEM. n=8CTR; n=14 SOD and n=14 SODHDAC4mKOmice. (One-way ANOVA reveals a significant effect
at each time point analyzed. 10weeks: F=5.02; df 2; p=0.01249; 11weeks: F=10.05; df 2; p=0.00039; 12weeks: F=8.75; df 2; p=0.000894; 13weeks: F=12.29; df 2; p b 0.0001;
14weeks: F=17.17; df 2; p b 0.0001; 15weeks: F=20.04; df 2; p b 0.0001; 16weeks: F=27.56; df 2; p b 0.0001; 17weeks: F=21; df 2; p b 0.0001; 18weeks: F=31.39; df 2; p b 0.0001
and interactions among variables; *p b 0.05; **p b 0.01 SOD vs SOD HDAC4mKO; $p b 0.05; $$p b 0.01 CTR vs SOD; #p b 0.05; ##p b 0.01 CTR vs SOD HDAC4mKO by Tukey's HSD test.)
(b) Age of ALS onset of SOD and SODHDAC4mKOmice. n=14mice for genotype. (*p=0.039 by log-rankMantel-Cox test). (c) Average days at theALS onset of SOD and SODHDAC4mKO
mice. Data are expressed as mean +/− SEM. n = 14 mice for each genotype (*p b 0.05 by Student's t-test.) (d) ALS progression of SOD and SOD HDAC4mKO mice. n = 14 mice for
genotype. (e) Average days of ALS progression of SOD and SOD HDAC4mKO mice. n = 14 mice for each genotype. (f) Muscle performance of CTR, SOD and SOD HDAC4mKO mice, by
grip test, at 12 weeks of age. Data are expressed as the mean of developed force over the mouse weight, +/− SEM. n = 8 CTR; n= 9 SOD and n= 12 SOD HDAC4mKO mice. (One-
way ANOVA reveals a significant effect among genotypes. F = 6.16; df 2; p = 0.009; and interaction: *p b 0.05; **p b 0.01 by Tukey's HSD test.) (g) Survival curve of SOD and SOD
HDAC4mKO mice. n = 15 SOD and n = 17 SOD HDAC4 mice. (h) Lifespan of SOD and SOD HDAC4mKO mice. Data are expressed as mean +/− SEM n = 15 SOD and n = 17 SOD
HDAC4 mice.
723E. Pigna et al. / EBioMedicine 40 (2019) 717–732innervation in SOD mice, TA muscles were stained with anti-
neurofilament antibody and analyzed using confocal microscopy. No
differences were detected at a preonset stage (data not shown). At
15weeks,while almost the totality of the CTRNMJs resulted innervated,
as expected, SODHDAC4mKOmice displayed a significantly higher per-
centage of denervated NMJs as compared to SOD littermates (Fig. 5e, f).
Importantly, NMJs and innervations formed and matured normallyin HDAC4mKO mice (Supplementary Fig. S1i), as previously reported
[7].
3.5. HDAC4 does not affect motoneuron survival in ALS
To define if HDAC4 from skeletal muscle impacts on the spinal cord,
histological and molecular analyses were performed on healthy CTR,
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725E. Pigna et al. / EBioMedicine 40 (2019) 717–732SOD, and SOD HDAC4mKO spinal cords over time. Despite the signifi-
cant decrease in motor neurons between CTR and SOD or SOD
HDAC4mKO mice, no differences in the spinal cord ventral horn mor-
phology, or in the number of motor neurons, visualized by NISSL stain-
ing, were detected between SOD and SOD HDAC4mKO mice at 12 or
15 weeks of age (Fig. 6a, b, e, f). Western blot analyses from ventral
roots for choline acetyltransferase (Chat), a motor neuron marker, con-
firmed that no significant changes in protein levels occurred between
SODand SODHDAC4mKOmice, even thoughSODmice showed a signif-
icant decrease in Chat expression compared to healthy CTR mice
(Fig. 6c, d, g, h), as expected. These results indicate that HDAC4 deletion
inmuscle does not affectmotoneuron bodies in the central nervous sys-
tem in ALS.
3.6. HDAC4 mediates the activation and progression of the catabolic path-
ways in ALS
Activation of catabolic pathways, such as the ubiquitin-proteasome
system (UPS) and autophagy, is associated with muscle atrophy
[27,28]. We wondered if the earlier occurrence of muscle atrophy in
SOD HDAC4mKO muscles could depend on a previous activation of
the catabolic pathways. Therefore, we monitored the activation of
both UPS and autophagic markers in GA muscles, at 12 and 15 weeks
of age. No significant differences regarding UPS activation were ob-
served among the experimental groups at 12 weeks of age, as assessed
by the expression levels of the E3 ubiquitin ligases Atrogin1 andMuRF1,
the amount of poly-ubiquitinated proteins and the proteasome activity
(Supplementary Fig. S3a–e). Importantly, no differences in UPS activa-
tion were registered at baseline between CTR and HDAC4mKO mice
[29]. No changes among genotypes occurred in the expression and pro-
tein levels of the two autophagic markers, LC3b and p62, at this time
point (Supplementary Fig. S3f–i), aswell as inHDAC4mKOmice at base-
line [29]. In contrast, at 15 weeks of age, a significant up-regulation of
MuRF1 expression was observed in SOD mice, compared to healthy
CTR, suggesting an activation of the proteasome pathway, but not in
SOD HDAC4mKO (Fig. 7a, b). The evaluation of poly-ubiquitinated pro-
teins and the quantification of the proteasome activity confirmed this
result. Indeed, poly-ubiquitinated proteins and proteasome activity
were significantly increased in SOD mice, when compared to CTR
(Fig. 7c–e). Conversely, SOD HDAC4mKO mice displayed levels of
poly-ubiquitinated proteins and proteasome activity similar to those
of CTR animals (Fig. 7c–e). Moreover, at 15 weeks of age, SOD mice
showed significant down-regulation of the LC3b expression but no
changes in p62 mRNA levels, when compared to CTR or SOD
HDAC4mKOmice (Fig. 7f, g). However, SODmice showed significant ac-
cumulation of both LC3b II and p62 proteins with respect to CTR mice,
suggesting a compromised autophagic flux, while protein accumulation
was not present in SOD HDAC4mKO mice (Fig. 7h–l). Significant differ-
ences in p62 protein levels among CTR, SOD and SODHDAC4mKOmice,
were also detected and quantified by immunofluorescence analyses, at
15 weeks of age (Fig. 7m, n), confirming the above results.
3.7. HDAC4 modulates different cellular pathways in ALS
To define the role of HDAC4 in ALS, we delineated the molecular
pathways globally modulated by HDAC4 in skeletal muscle.Fig. 4. Deletion of HDAC4 worsens muscle atrophy in ALS. (a, b, c) TA muscle weight of healt
expressed as mean of TA weight relative to SOD littermates +/− SEM. n = 5 CTR, n = 6
HDAC4mKO mice in b; n = 10 CTR, n = 8 SOD and n = 8 SOD HDAC4mKO mice in c. (One-w
b 0.0001 in b; F = 106.6; df 2; p b 0.0001 in c; and interaction: **p b 0.01 SOD vs SOD HDAC4
(d, f, h) Representative images of TA muscle histology at 12, 15 or 18 weeks of age. Scale bar =
at 12, 15 or 18 weeks of age. Data are expressed as mean +/− SEM. n = 3 mice per each
significant effect in the following classes: 2001–2500 μm2 F = 29.28; df 2; p= 0.0008 and N
1001–1500 μm2 F = 18.97; df 2; p = 0.0009; in 2501–3000 μm2 F = 5.2; df 2; p = 0.035; in 3
and in 1001–1500 μm2 F = 22.9; df 2; p= 0.0004; in 3001–3500 μm2 F = 15.08; df 2; p = 0.
SOD HDAC4mKO; $p b 0.05; $$p b 0.01 CTR vs SOD; #p b 0.05; ##p b 0.01 CTR vs SOD HDAC4Transcriptome analysis was performed by comparing SOD and SOD
HDAC4mKO GA muscles, at the onset of ALS, i.e. at 14 weeks of age.
Total RNA was harvested from five SOD and six SOD HDAC4mKO
mice. Samples were pooled together and sequenced as duplicates of
SOD and SOD HDAC4mKOmuscles. HDAC4 significantly (p b .05) mod-
ulated 2508 genes: 49% resulted up-regulated in SODHDAC4mKOmice,
while 51% was down-regulated, as depicted in the MA-plot graph
(Supplementary Fig. S4a). Gene ontology analysis revealed that,
among biological processes, HDAC4 mainly affected intracellular signal
transduction (phosphorylation, protein phosphorylation, positive regu-
lation of transcription from RNA polymerase II promoter, positive regu-
lation of transcription, response to hypoxia, intracellular signal
transduction), muscle development and contraction (muscle contrac-
tion, skeletal muscle tissue development, heart development, positive
regulation of myoblast differentiation, negative regulation of cell
growth), metabolism (cellular response to insulin signaling, insulin
receptor signaling pathway, lipid metabolic process), ubiquitin-
dependent protein catabolic process, aging and the nervous system
(dendrite morphogenesis) (Fig. 8a). Top enriched gene sets between
SOD HDAC4mKO and SOD mice nicely correlated with the gene ontol-
ogy results and with the mutant phenotype. Indeed, in the reactome
pathways, muscle contraction, transcriptional regulation by Runx2, a
knownHDAC4 target [30] andmetabolismwere found (Supplementary
Fig. S4b). In disease ontology pathways,muscular disease, muscle tissue
disease andmyopathywere the top three hits (Supplementary Fig. S4c).
A heatmap of the top 100 most significantly modulated genes revealed
that HDAC4 modulates genes involved in response to denervation in
ALS (Fig. 8b and Supplementary table). Among these, the expression
levels of myogenin, Chrna1 and Chrng were confirmed to be down-
regulated in SOD HDAC4mKO compared to SOD mice, by real-time
PCR on independent samples (Fig. 8c–e). Moreover, Dach2 expression
was significantly up-regulated, while miR-206 significantly down-
regulated in SOD HDAC4mKO mice, if compared to SOD (Fig. 8f, g), as
expected [7,9]. Of note, SOD1 expression did not significantly change
between SOD and SOD HDAC4mKO mice, despite the significant in-
crease compared to healthy CTR mice (Supplementary Fig. S4d). An in-
teresting gene network and top upstream modulator, the uncoupling
protein 1 (UCP1), were identified by Ingenuity Pathway Analysis (IPA)
(Supplementary Fig. S4e). Considering that the over-expression of
UCP1 in skeletalmuscle in amousemodel of ALS is sufficient to increase
NMJ instability and muscle denervation, worsening ALS features [31],
we monitored the expression of UCP1 in the skeletal muscle of SOD
and SOD HDAC4mKO mice, at 14 weeks of age. UCP1 resulted signifi-
cantly up-regulated in SOD HDAC4mKO mice, with respect to SOD
mice (Fig. 8h), suggesting it may be a key mediator of the SOD
HDAC4mKO phenotype. Of note, the expression of none of thesemolec-
ular markers resulted perturbed in HDAC4mKO mice at baseline (Sup-
plementary Fig. S1 l–o).
4. Discussion
ALS is a progressive, still incurable neurodegenerative disease. Al-
though the primary cause of ALS is motor neuron degeneration, skeletal
muscle emerged as a primary target of the disease. As the etymology
suggests, “a-myo-trophic” (from Greek) literally means “lack of muscle
nourishment”. Without the nerve, skeletal muscle undergoeshy control (CTR), SOD and SOD HDAC4mKO mice at 12, 15 or 18 weeks of age. Data are
SOD and n = 8 SOD HDAC4mKO mice in a; n = 5 CTR, n = 8 SOD and n = 10 SOD
ay ANOVA reveals a significant effect: F = 30.91; df 2; p b 0.0001 in a; F = 48.01; df 2; p
mKO; $$p b 0.01 CTR vs SOD; ##p b 0.01 CTR vs SOD HDAC4mKO by Tukey's HSD test.)
50 μm. (e, g, i) Myofiber CSA distribution of CTR, SOD and SOD HDAC4mKO TA muscles
genotype in e; n = 4 mice per each genotype in g and i. (One-way ANOVA reveals a
3500 μm2 F = 9.89; df 2; p = 0.012 in e; in 501–100 μm2 F = 7.86; df 2; p = 0.012; in
001–3500 μm2 F = 8.03; df 2; p = 0.012; in N3501 μm2 F = 16.85; df 2; p = 0.001 in g;
001 and in N3501 μm2 F = 27.14; df 2; p = 0.0001 in i; and interaction: *p b 0.05 SOD vs
mKO by Tukey's HSD test.)
Fig. 5. HDAC4 alters NMJ structure and innervation in ALS. (a) Representative images of NMJ postsynaptic machinery in healthy control (CTR), SOD and SOD HDAC4mKO TAmuscles, at
15weeks of age. Right images show processing during NMJ analysis for automated quantification of AChR and endplate areas. Scale bar= 10 μm. (b) Quantification of AChR, (c) endplate
and (d) perforation areas. Data are expressed asmean+/− SEM. n=3mice for each genotype. (One-wayANOVA reveals a significant effect: F=9.13; df 2; p=0.015 in b; F=9.64; df 2;
p=0.007 in c; F=18.12; df 2; p=0.002 ind; and interaction: *p b 0.05; **p b 0.01by Tukey'sHSD test.) (e) Representative images of innervated (I) anddenervated (D)NMJs, at 15weeks
of age. Scale bar= 10 μm. (f) Quantification of innervated and denervated NMJs in CTR, SOD and SOD HDAC4mKOmice. Data are expressed asmean+/− SEM. n= 3 CTR; n=5 SOD or
SODHDAC4mKOmice. (Two-wayANOVA reveals a significant effect of denervation: F=5.35; df 1; p=0.033 and interaction between the genotype and denervation: F=124.64; df 2; p b
0.0001; *p b 0.05; **p b 0.01; $$p b 0.01 D SOD vs D CTR; ##p b 0.01 D SOD HDAC4mKO vs D CTR by Tukey's HSD test.)
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728 E. Pigna et al. / EBioMedicine 40 (2019) 717–732progressive atrophy, and this contributes to the progression of the dis-
ease, coherentlywith the “dying-back”model of the disease [4]. Accord-
ing to this theory, since muscle weakness and NMJ degeneration
precede and contribute to motor neuron loss, treatments aimed at im-
proving skeletal muscles may delay motor impairment [32]. In agree-
ment, treatments to rescue motor neurons have shown only limited
success in ALS mice or patients.
HDAC4 is a crucial mediator of skeletal muscle atrophy and reinner-
vation following denervation [7,9]. The expression of HDAC4 in the skel-
etal muscle of ALS patients correlates with the severity of the disease
progression [12,13]. Our present data complement this information,
registering an early up-regulation of HDAC4 in muscle at 12 weeks of
age, followed by a decrease at 15 weeks of age. This expression pattern
strongly suggests a function of HDAC4 in skeletalmuscle at the preonset
stage. Class II HDACi administration partially ameliorated ALS features
in mice [19], although failing to clarify the specific role of each class II
HDACmember in the progression of the disease.Moreover, even though
the continuous studies and the advances in pharmacology improved the
quality of HDACi and reduced the side effects, long-term use of HDACi is
not well-tolerated in humans [33]. Some side effects can be routinely
managed (e.g. nausea and vomiting); others are transient and reversible
(such as thrombocytopenia, neutropenia, and anemia), but most of
themnegatively affect the patients' quality of life. The primary toxicities
associatedwith HDACi are nausea, vomiting, anorexia, and fatigue, with
bodyweight loss and severe neurological events, such asneurocognitive
impairment and status epilepticus [34–37]. Some side effects and the
partial ineffectiveness of the treatments, as well, may depend on the
broad action of the pan- or class-specific HDACi. Based on this evidence,
understanding the molecular mechanism modulated by each HDAC
member is a prerequisite for ameliorating HDACi-based therapies.
In this study, we elucidated the HDAC4 role in skeletal muscle in ALS
by using a genetic approach. Muscle-specific mutant mice (SOD
HDAC4mKO)were generated andHDAC4 expression in skeletal muscle,
but not in spinal cords, was significantly downregulated if compared to
SOD littermates and comparable to healthy CTR mice. SOD transgenic
mice are a widely used animal model in the study of ALS. In these
mice, the transgenic over-expression of mutated human SOD1, a gene
mutated in a subset of familial ALS, results in a phenotype closely reca-
pitulating the human disease features [38]. Hindlimb tremors, as first
clinical signs of motor neuron disease, occur around 12 weeks of age
in SOD mice [39], although reduced rotarod performance was detected
earlier, at around 8.5 weeks of age, and correlates with skeletal muscle
denervation [40]. Significant body weight loss is registered around
14 weeks of age, while muscle atrophy is detected by MRI imaging
around 8.5weeks of age in SODmice [39,40]. Deletion of HDAC4 in skel-
etal muscle drastically worsened the pathological features of ALS by
causing a precocious disease onset and by inducing a significant de-
crease in body weight and muscle atrophy. Interestingly, SOD
HDAC4mKOmice showed a significant reduction in muscle strength in
as early as 12 weeks. At this age, no differences in body weight, muscle
mass or CSA were detected between genotypes, thus indicating that in-
trinsic defects in myofibers occurred before the decrease in body
weight, supporting the “dying-back” model. Besides, a significant in-
crease in muscle atrophy in SOD HDAC4mKO mice was revealed at the
late stage of the disease, while the presence of very small and very big
myofibers was registered in SOD muscles.
Neuromuscular junction degeneration is one of the main ALS
features, causing neurogenic muscle atrophy and, eventually, lethal
respiratory failure [41]. Skeletal muscle actively influences theFig. 6. Skeletal muscle-specific HDAC4 deletion does not affect the central nervous system in A
SOD HDAC4mKOmice, stained with hematoxylin and eosin (left panel; scale bar = 20 μm) and
CTR, SOD and SOD HDAC4mKO mice, at 12 or 15 weeks of age. Data are expressed as mean +/
1112.3; df 2; p b 0.0001 in b; F = 54.14; df 2; p = 0.0001 in f; **p b 0.01 by Tukey's HSD test.)
ventral roots of spinal nerves, over CTR, at 12 or 15 weeks of age. Gapdh was used as a loading
ANOVA reveals a significant effect: F = 6.34; df 2; p = 0.0147 in d; F = 9.98; df 2; p = 0.0123neurodegeneration process in ALS by expressing and releasing signals
that influence the maintenance of synaptic connections, axonal growth
and neuron survival [42,43]. Aiming to investigate if HDAC4 affected
muscle-nerve interface, evaluation of NMJ shape and innervation was
performed over time. While no significant differences were detected
among genotypes at 12 weeks of age, at 15 weeks, a significant reduc-
tion in the synapse area and a higher number of denervated NMJ were
found in SOD HDAC4mKO mice. These data demonstrate that skeletal
muscle HDAC4 regulates ALS onset, having a protective role for NMJs
and muscle innervations, even though NMJ development was not af-
fected by HDAC4 in HDAC4mKOmice, as already reported [7]. In agree-
mentwith this phenotype, the expression of an important neurotrophic
factor in ALS progression, i.e., glial cell-derived neurotrophic factor
(GDNF) [44], was significantly down-regulated in the transcriptome of
SOD HDAC4mKO mice (Supplementary Fig. S4f). To investigate if
HDAC4 might retrogradely affect the central nervous system in ALS,
motor neurons were examined over time, by histological andmolecular
analyses. Interestingly, no differences were detected between the two
experimental groups, indicating that HDAC4 does not affect motor neu-
ron survival in ALS. Of note, all the differences seen between SOD
HDAC4mKO and SODmice, i.e., body andmuscle weight, muscle perfor-
mance and histology, NMJs and innervations, confirmed a specific stress
response role of HDAC4 in skeletal muscle in pathological conditions,
since no differences were detected at baseline in HDAC4mKO mice
[9,25,29].
The decline in body weight correlated with muscle atrophy in SOD
HDAC4mKO mice, indicating the importance of preserving skeletal
muscle mass in ALS. To search for the molecular mechanisms underly-
ing the enhanced atrophic phenotype, the activation of the two major
catabolic pathways in skeletal muscle, i.e., the UPS and autophagy
[45], was examined. SOD HDAC4mKO mice did not trigger UPS activa-
tion in ALS, coherently with the HDAC4 function following long-term
denervation [29]. The lack of UPS activation could contribute toworsen-
ing theALS phenotype in SODHDAC4mKOmice. Accordingly, treatment
with a known activator of the proteasome, i.e., methylene blue, pre-
serves the neuromuscular function of SODmice [46]. Regarding autoph-
agy, at 15 weeks, SOD mice showed a significant accumulation of LC3b
and p62 proteins, without a corresponding increase in gene expression,
thus suggesting an impairment of the autophagy flux, in agreement
with previous observations [47]. Instead, SODHDAC4mKOmice showed
expression levels of autophagic markers similar to those of healthy CTR
mice, thus suggesting that HDAC4mediates the autophagic flux in skel-
etalmuscle in ALS, as previously observed following long-termdenerva-
tion [29]. Dysregulation of the autophagic flux occurs in various
neurodegenerative diseases [48]. Regarding ALS, even though an in-
crease in autophagy was found in the spinal cords of ALS patients and
animalmodels [49–52], controversial results were also reported. For in-
stance, a study showed that treatment with rapamycin, an autophagy
activator, increased degradation of misfolded proteins and decreased
the autophagosome accumulation in motor neurons [52]. Others re-
ported that rapamycin administration increased motor neuron degen-
eration and negatively affected muscle performance in ALS mouse
models [49,53], thus rendering it difficult to consider rapamycin as a po-
tential treatment [54]. In skeletal muscle, autophagy was first described
as one of the major intracellular mechanisms involved in atrophy in a
mouse model of ALS [5]. However, it was recently demonstrated that
the autophagic flux is impaired in SOD mice skeletal muscle, and prob-
ably abnormal autophagy contributes to muscle degeneration in ALS
progression [47].LS. (a, e) Representative pictures of spinal cord sections of healthy control (CTR), SOD and
NISSL staining (right panel; scale bar = 50 μm). (b, f) Quantification of motor neurons of
− SEM. n= 3mice for each genotype. (One-way ANOVA reveals a significant effect: F =
(c, g)Western blot analysis and (d, h) densitometry for Chat in SOD and SOD HDAC4mKO
control. Data are presented as mean +/− SEM. n= 3mice for each genotype. (One-way
in h; and interaction: *p b 0.05 by Tukey's HSD test.)
Fig. 7. SOD HDAC4mKOmice do not activate the catabolic pathways. (a) Expression levels of Atrogin1 and (b) MuRF1 in healthy control (CTR), SOD and SOD HDAC4mKO GAmuscles, at
15 weeks of age, by real-time PCR. n=4mice for each genotype. (One-way ANOVA reveals a significant effect: F = 5.45; df 2; p = 0.032; and interaction *p b 0.05 by Tukey's HSD test.)
(c) Western blot analyses and (d) quantification of poly-ubiquitinated proteins in CTR, SOD and SOD HDAC4mKO GAmuscles, at 15 weeks of age. Alpha-tubulin was used as a loading
control. n= 3mice for each genotype. (One-way ANOVA reveals a significant effect among genotypes (F = 5.7; df 2; p = 0.018); *p b 0.05 by Tukey's HSD test.) (e) Proteasome activity
in CTR, SOD and SOD HDAC4mKO GAmuscles, at 15 weeks of age. n = 3 mice for each genotype. (One-way ANOVA reveals a significant effect: F = 6.85; df 2; p= .018; and interaction:
*p b 0.05 by Tukey's HSD test.) (f) LC3b and (g) p62 expression levels in CTR, SOD and SOD HDAC4mKO GAmuscles, at 15 weeks of age, by real-time PCR. n= 4mice for each genotype.
(One-way ANOVA reveals a significant effect in f: F = 17.1; df 2; p = 0.0004; and interaction: **p b 0.01 by Tukey's HSD test.) (h) Western blot analyses and (i, l) densitometry for LC3b
and p62 proteins of CTR, SOD and SOD HDAC4mKO GAmuscles at 15 weeks of age. Alpha-tubulin was used as a loading control. n= 5mice for each genotype. Data are shown as mean
± SEM, over CTR mice. (One-way ANOVA reveals a significant effect: F = 6.17; df 2; p = 0.014 in i; F = 16.38; df 2; p = 0.0003 in l; and interaction: *p b 0.05 by Tukey's HSD test.)
(m) Representative images and (n) quantification of immunofluorescence for p62 of CTR, SOD and SOD HDAC4mKOmuscles at 15 weeks of age. Scale bar = 25 μm. Data are presented
as mean +/− SEM. n=3mice for each genotype. (One-way ANOVA reveals a significant effect: F = 12.84; df 2; p= 0.0067; and interaction: *p b 0.05; **p b 0.01 by Tukey's HSD test.)
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Fig. 8. HDAC4 modulates gene expression in GA skeletal muscle in ALS. (a) Gene ontology of the biological processes most significantly modulated by HDAC4 in ALS. (b) Heatmap of top
100 most significantly differentially expressed genes. Significance is determined by Benjamini-Hochberg corrected p-values between the two genotypes. (c-h) Expression levels of indi-
cated genes in SODHDAC4mKOmice, relative to SOD littermates, at 14weeks of age, by real-time PCR. Data are expressed asmean+/− SEM. n=6SOD;n=5 SODHDAC4mKOmice. (*p
b 0.05; **p b 0.01 by Student's t-test.)
730 E. Pigna et al. / EBioMedicine 40 (2019) 717–732
731E. Pigna et al. / EBioMedicine 40 (2019) 717–732Muscle regeneration has not been reported as a clinical feature of
ALS. Although HDAC4 is crucial for satellite cell proliferation and differ-
entiation [55], satellite cells do express HDAC4 until myogenin expres-
sion occurs in SOD HDAC4mKO mice, and HDAC4mKO satellite cells
do not show impaired differentiation ability in vitro if compared to con-
trols (data not shown). From all these considerations, we believe
HDAC4 functions in ALS are beyond the regulation of muscle
regeneration.
Aiming to identify the molecular mechanisms regulated by HDAC4
in ALS, a transcriptome analysis was performed by comparing the skel-
etal muscle of SOD and SODHDAC4 at the onset of the disease. Bioinfor-
matic analysis revealed that HDAC4 mostly modulates intracellular
signal transduction, muscle development, metabolism and ubiquitin-
dependent catabolism in ALS muscles, in line with the phenotype ob-
served. Additional bioinformatic analyses of the top enriched gene sets
confirmed that HDAC4 affects muscle contraction and metabolism and
that the transcriptomedata effectively reflectmuscle disease andmyop-
athy. A heatmap of the 100most significantlymodulated genes revealed
that HDAC4 mediates skeletal muscle response to denervation in ALS.
Indeed, HDAC4 is necessary for the activation of several downstream
cellular responses, such as the activation of UPS, autophagy and oxida-
tive stress response [29]. IPA analysis of the differentially expressed
genes identified a gene network controlled by UCP1 and UCP1 expres-
sion resulted in up-regulated in SOD HDAC4mKO muscles, but not in
HDAC4mKO ones. UCP1 is a mitochondrial protein, typically expressed
in brown adipose tissue, that induces non-shivering thermogenesis by
uncoupling the mitochondrial electron transport chain [56,57]. Overex-
pression of UCP1 in skeletal muscle is sufficient to induce muscle atro-
phy, without activating the UPS, to stimulate hypermetabolism and
mild motoneuron degeneration [31]. Most importantly, overexpression
of UCP1 in the skeletal muscle of SOD mice reduced NMJ stability and
contributed to muscle denervation, similarly to deletion of HDAC4 in
ALS mice. Accordingly, muscle innervation is also controlled by metab-
olism. Indeed, hypermetabolism induces a chronic energy deficit in
the skeletal muscle of SOD mice, preceding and contributing to muscle
denervation and ALS progression [58]. As proof of concept, a high-fat
diet aimed to improve the energy deficit is sufficient to improvemuscle
innervation and prolong the survival of SOD mice, though this strategy
has not been suggested for ALS patients due to expected side effect
[59]. Moreover, alterations in mitochondrial network and function
have been described in skeletal muscle of ALS mice and patients at the
preonset stage, being sufficient to cause NMJ degeneration and death
ofmotoneurons inmice, worsening the ALS progression [60,61]. Several
pharmacological or gene therapy approaches aimed at resolving mito-
chondrial dysfunction, such as increasing mitochondrial function and
survival or reducing oxidative stress, have been tried. However, despite
showing promising results in animal models, ALS remains an incurable
and fatal disease.5. Conclusions
ALS is emerging as a multisystemic disease in which skeletal muscle
actively participates with structural and metabolic alterations, contrib-
uting to ALS progression in a “dying back” process. This study identified
new functions of HDAC4 in skeletalmuscle in ALS,whose deletion is suf-
ficient to induce an earlier onset of the disease, characterized bymuscle
denervation, decrease in NMJ size and functional deficit, accompanied
by exacerbated muscle atrophy over time. Given that pan- or class II
HDACi indirectly affect HDAC4 targets, our study provides the experi-
mental basis to reconsider the use of such non-specific drugs for the
treatment of ALS. More studies are necessary to better delineate the
functions of each member of the HDAC superfamily in ALS, in order to
propose more specific and efficient therapeutic approaches.
Supplementary data to this article can be found online at https://doi.
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